<DOC>
	<DOC>NCT02634424</DOC>
	<brief_summary>The purpose of this study is to evaluate the implementation of pharmacokinetic (PK) driven prophylaxis in current clinical practice</brief_summary>
	<brief_title>PK Driven Prophylaxis for Hemophilia A</brief_title>
	<detailed_description>Starting from 3 pharmacokinetic (PK) points, data are entered in the PK calculator device, and treatment dose is adjusted following the results of PK values obtained and clinical bleeding data</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male Patient Severe or moderately severe haemophilia A (FVIII = 2 %), preventively treated (processing) by ADVATE for at least 6 months, At last 6 years old, An informed consent must be signed by the patient or his legal representative for the patients minor. Affiliated to a national insurance scheme Previous or actual treatment with FVIII inhibitors &gt; 0,6 UB at the selection Induction of immune tolerance Planned orthopedic surgery for the 18 next months Any other haemostatic pathology Any treatment interacting on the haemostasis Patient under guardianship Patient participating in another biomedical research</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Prophylaxy</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Bayesian</keyword>
</DOC>